

Resource Summary Report

Generated by [dkNET](#) on Aug 18, 2026

Ultra-LEAF(TM) Purified anti-mouse CD28

RRID:AB_11147170

Type: Antibody

Proper Citation

(BioLegend Cat# 102116, RRID:AB_11147170)

Antibody Information

URL: http://antibodyregistry.org/AB_11147170

Proper Citation: (BioLegend Cat# 102116, RRID:AB_11147170)

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC, IP, IHC-F, Costim, Block

Antibody Name: Ultra-LEAF(TM) Purified anti-mouse CD28

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: Clone 37.51

Antibody ID: AB_11147170

Vendor: BioLegend

Catalog Number: 102116

Alternative Catalog Numbers: 102121, 102132, 102131, 102122, 102115

Record Creation Time: 20260526T044338+0000

Record Last Update: 20260526T044338+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 97 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. *Cell*, 189(1), 233.

Wang H, et al. (2026) Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity. *Cancer research communications*, 6(3), 500.

Arumugam P, et al. (2026) Mitochondrial transfer to granulocytic myeloid-derived suppressor cells augments immunosuppressive activity. *Cell reports*, 45(3), 117057.

Li Y, et al. (2026) CpG 1018 augments mRNA vaccine-induced anti-tumor immunity by potentiating CD8+ T cell responses. *Molecular therapy. Oncology*, 34(2), 201230.

Yao B, et al. (2026) Divergent tumor immunity determined by bacteria-cancer cell engagement. *Cell*, 189(6), 1748.

Chen S, et al. (2026) 16-h fasting optimizes cancer immunotherapy in mice and humans. *Cell metabolism*, 38(5), 944.

Mochizuki-Ono C, et al. (2026) PLA2G12A-driven extracellular vesicle-lipid signaling amplifies pathogenic T cell responses in inflammatory diseases. *Cell reports*, 45(6), 117391.

Tripathi A, et al. (2026) Protocol for intranuclear Nrf2 detection in activated mouse, human, and Jurkat T cells by spectral flow cytometry. *STAR protocols*, 7(1), 104360.

Li X, et al. (2026) The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. *Immunity*, 59(1), 98.

Zhang P, et al. (2026) Sympathetic-epithelial crosstalk governs tissue-resident memory T cell immunosurveillance in the skin. *Cell*, 189(5), 1323.

Kureshi CTS, et al. (2026) Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. *Cancer cell*, 44(7), 1381.

Liu Z, et al. (2026) Activation-gated, T cell-restricted silencing of Dapk1 enhances Bacille Calmette-Guérin-elicited protective CD4+ memory. *iScience*, 29(5), 115593.

De la Torre Medina J, et al. (2026) Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway. *Molecular cancer therapeutics*, 25(6), 957.

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. *Cell reports*, 45(1), 116796.

Dong P, et al. (2026) Enhanced HIF-1 α cooperation by a human ROR γ t mutant potentiates Th17 pathogenicity. *Cell reports*, 45(4), 117123.

Pang J, et al. (2026) Law-NQO1 redox boosts the pentose phosphate pathway to confer stem-like properties and antitumor durability in effector CD8+ T cells. *Cell chemical biology*, 33(3), 321.

Scaglione M, et al. (2026) Metabolic and transcriptional plasticity supports CD8+ T cell resilience and anti-tumor immunity under nutrient stress. *Immunity*, 59(5), 1344.

Yang S, et al. (2026) Oat- β -glucan potentiates anti-PD-1 efficacy through *Faecalibacterium prausnitzii*-derived butyrate and indole-3-propionic acid. *Cell host & microbe*, 34(7), 1333.

Brown ME, et al. (2025) Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function. *Diabetologia*, 68(2), 397.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. *Cancer cell*, 43(3), 503.